Protein phosphorylation is a cornerstone of cellular communication, orchestrating rapid and precise responses to ...

Current mortality prediction models for patients with kidney failure may introduce bias and applicability concerns in ...

Now aged 32, the entrepreneur is sharing his story to raise awareness of kidney disease, which affects 35.5 million Americans, according to the American Kidney Fund. Blake Shusterman, a ...

A Phase 3 clinical trial found that injections of the semaglutide medication once weekly reduced the risk of kidney disease worsening by 24% in people who also had diabetes. It also reduced the ...

By Dani Blum The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have both Type 2 diabetes and chronic kidney disease.

Of 111,155 tuberculosis diagnoses, researchers found 2,892 patients had kidney failure. The annual tuberculosis rate ranged from 26.1 to 45.4 per 100,000 patients with kidney failure. The ...

A team led by Dr. Erik Larson, vice chair of the Department of Biomedical Sciences, has uncovered the cause of a common kidney disease after eight years of research, a news release from WMed said.

Use of proton pump inhibitors appears to increase the risk for kidney failure among patients with CKD. Use of proton pump inhibitors (PPIs) may spur progression to kidney failure in patients with ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

In its early stages, kidney disease may not cause any symptoms or signs. However, as it progresses, it can cause symptoms such as itchy skin, pruritus, and a rash. Around 35.5 million adults in ...

Polycystic kidney disease (PKD) is a genetic disorder whereby a large number of cysts develop primarily within the kidneys, but also in other organs. PKD can be autosomal dominant (one mutated ...

Fibrosis has a key role in the progression of kidney disease and kidney failure. Here, the authors examine current options for targeting pro-fibrotic pathways, including the anti-fibrotic ...